Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
J Bacteriol ; 190(3): 1128-33, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18039768

RESUMEN

The sigG gene of Mycobacterium tuberculosis was disrupted by homologous recombination, and the genes regulated by SigG were examined by real-time reverse-transcription PCR and microarray studies. The SigG consensus promoter recognition sequence was identified as GCGNGT-N15-18-CGANCA. A DeltasigG mutant was found to be more resistant to mitomycin C treatment than the wild-type strain, indicating that it may be involved in the SOS response in M. tuberculosis.


Asunto(s)
Proteínas Bacterianas/metabolismo , ARN Polimerasas Dirigidas por ADN/metabolismo , Regulación Bacteriana de la Expresión Génica , Respuesta al Choque Térmico , Mycobacterium tuberculosis/fisiología , Respuesta SOS en Genética , Factor sigma/metabolismo , Animales , Proteínas Bacterianas/genética , Secuencia de Bases , Línea Celular , ARN Polimerasas Dirigidas por ADN/genética , Humanos , Macrófagos Alveolares/microbiología , Ratones , Datos de Secuencia Molecular , Mycobacterium tuberculosis/metabolismo , Mycobacterium tuberculosis/patogenicidad , Análisis de Secuencia por Matrices de Oligonucleótidos , Regiones Promotoras Genéticas , Recombinación Genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factor sigma/genética
2.
BMC Microbiol ; 8: 151, 2008 Sep 17.
Artículo en Inglés | MEDLINE | ID: mdl-18798983

RESUMEN

BACKGROUND: Mouse virulence assessments of certain Mycobacterium tuberculosis mutants have revealed an immunopathology defect in which high tissue CFU counts are observed but the tissue pathology and lethality are reduced. M. tuberculosis mutants which grow and persist in the mouse lungs, but have attenuated disease progression, have the immunopathology (imp) phenotype. The antigenic properties of these strains may alter the progression of disease due to a reduction in host immune cell recruitment to the lungs resulting in disease attenuation and prolonged host survival. RESULTS: In this study we focused on the mouse immune response to one such mutant; the M. tuberculosis Delta sigC mutant. Aerosol infection of DBA/2 and SCID mice with the M. tuberculosis Delta sigC mutant, complemented mutant and wild type strain showed proliferation of mutant bacilli in mouse lungs, but with decreased inflammation and mortality in DBA/2 mice. SCID mice shared the same phenotype as the DBA/2 mice in response to the Delta sigC mutant, however, they succumbed to the infection faster. Bronchoalveolar lavage (BAL) fluid analysis revealed elevated numbers of infiltrating neutrophils in the lungs of mice infected with wild type and complemented Delta sigC mutant strains but not in mice infected with the Delta sigC mutant. In addition, DBA/2 mice infected with the Delta sigC mutant had reduced levels of TNF-alpha, IL-1beta, IL-6 and IFN-gamma in the lungs. Similarly, there was a reduction in proinflammatory cytokines in the lungs of SCID mice. In contrast to the mouse model, the Delta sigC mutant had reduced initial growth in guinea pig lungs. A possible mechanism of attenuation in the Delta sigC mutant may be a reduction in neutrophilic-influx in the alveolar spaces of the lungs, and decreased proinflammatory cytokine secretion. In contrast to mouse data, the M. tuberculosis Delta sigC mutant proliferates slowly in guinea pig lungs, a setting characterized by caseating necrosis. CONCLUSION: Our observations suggest that the immunopathology phenotype is associated with the inability to trigger a strong early immune response, resulting in disease attenuation. While macrophages and T cells have been shown to be important in containing M. tuberculosis disease our study has shown that neutrophils may also play an important role in the containment of this organism.


Asunto(s)
Proteínas Bacterianas/inmunología , Citocinas/inmunología , Proteínas de Unión al ADN/inmunología , Mycobacterium tuberculosis/inmunología , Infiltración Neutrófila , Factor sigma/inmunología , Tuberculosis Pulmonar/inmunología , Animales , Animales no Consanguíneos , Proteínas Bacterianas/genética , Proteínas de Unión al ADN/genética , Progresión de la Enfermedad , Femenino , Cobayas , Humanos , Huésped Inmunocomprometido , Inmunoterapia , Pulmón/inmunología , Pulmón/microbiología , Pulmón/patología , Ratones , Ratones Endogámicos DBA , Ratones SCID , Mutación , Mycobacterium tuberculosis/genética , Mycobacterium tuberculosis/crecimiento & desarrollo , Factor sigma/genética , Tuberculosis Pulmonar/patología , Tuberculosis Pulmonar/terapia
3.
N Engl J Med ; 346(14): 1054-9, 2002 Apr 04.
Artículo en Inglés | MEDLINE | ID: mdl-11932472

RESUMEN

BACKGROUND: Familial adenomatous polyposis is caused by a germ-line mutation in the adenomatous polyposis coli gene and is characterized by the development of hundreds of colorectal adenomas and, eventually, colorectal cancer. Nonsteroidal antiinflammatory drugs can cause regression of adenomas, but whether they can prevent adenomas is unknown. METHODS: We conducted a randomized, double-blind, placebo-controlled study of 41 young subjects (age range, 8 to 25 years) who were genotypically affected with familial adenomatous polyposis but phenotypically unaffected. The subjects received either 75 or 150 mg of sulindac orally twice a day or identical-appearing placebo tablets for 48 months. The number and size of new adenomas and side effects of therapy were evaluated every four months for four years, and the levels of five major prostaglandins were serially measured in biopsy specimens of normal-appearing colorectal mucosa. RESULTS: After four years of treatment, the average rate of compliance exceeded 76 percent in the sulindac group, and mucosal prostaglandin levels were lower in this group than in the placebo group. During the course of the study, adenomas developed in 9 of 21 subjects (43 percent) in the sulindac group and 11 of 20 subjects in the placebo group (55 percent) (P=0.54). There were no significant differences in the mean number (P=0.69) or size (P=0.17) of polyps between the groups. Sulindac did not slow the development of adenomas, according to an evaluation involving linear longitudinal methods. CONCLUSIONS: Standard doses of sulindac did not prevent the development of adenomas in subjects with familial adenomatous polyposis.


Asunto(s)
Poliposis Adenomatosa del Colon/prevención & control , Antiinflamatorios no Esteroideos/uso terapéutico , Sulindac/uso terapéutico , Poliposis Adenomatosa del Colon/genética , Adolescente , Adulto , Antiinflamatorios no Esteroideos/efectos adversos , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Niño , Método Doble Ciego , Femenino , Genes APC , Humanos , Masculino , Mutación , Cooperación del Paciente , Prostaglandinas/análisis , Recto/química , Recto/patología , Análisis de Regresión , Sulindac/efectos adversos , Tromboxano B2/análisis
4.
Nucleic Acids Res ; 30(13): 2736-41, 2002 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-12087155

RESUMEN

KLF4 (Krüppel-like factor 4 or gut-enriched Krüppel-like factor, GKLF) and KLF5 (Krüppel-like factor 5 or intestinal-enriched Krüppel-like factor, IKLF) are two closely related members of the zinc finger-containing Krüppel-like factor family of transcription factors. Although both genes are expressed in the intestinal epithelium, their distributions are different: Klf4 is primarily expressed in the terminally differentiated villus cells while Klf5 is primarily in the proliferating crypt cells. Previous studies show that Klf4 is a negative regulator of cell proliferation and Klf5 is a positive regulator of cell proliferation. In this study, we demonstrate that Klf5 binds to a number of cis-DNA elements that have previously been shown to bind to Klf4. However, while Klf4 activates the promoter of its own gene, Klf5 suppresses the Klf4 promoter. Moreover, Klf5 abrogates the activating effect of Klf4 on the Klf4 promoter and Klf4 abrogates the inhibitory effect of Klf5 on the same promoter. An explanation of this competing effect is due to physical competition of the two proteins for binding to cognate DNA sequence. The complementary tissue localization of expression of Klf4 and Klf5 and the opposing effect of the two Klfs on the Klf4 promoter activity may provide a basis for the coordinated regulation of expression of the Klf4 gene in the intestinal epithelium.


Asunto(s)
Proteínas de Unión al ADN/metabolismo , Regiones Promotoras Genéticas/genética , Transactivadores/metabolismo , Factores de Transcripción/metabolismo , Animales , Unión Competitiva , Células CHO , Cricetinae , ADN/genética , ADN/metabolismo , Proteínas de Unión al ADN/genética , Ensayo de Cambio de Movilidad Electroforética , Regulación de la Expresión Génica , Factor 4 Similar a Kruppel , Factores de Transcripción de Tipo Kruppel , Plásmidos/genética , Unión Proteica , Transactivadores/genética , Factores de Transcripción/genética
5.
Nat Commun ; 3: 753, 2012 Mar 20.
Artículo en Inglés | MEDLINE | ID: mdl-22434196

RESUMEN

The emergence of multi- and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respectively) has intensified the critical public health implications of this global disease. The fitness of Mycobacterium tuberculosis (M.tb.) strains exhibiting MDR and XDR phenotypes is of fundamental importance in predicting whether the MDR-/XDR-TB epidemic will be sustained across the human population. Here we describe a potential mechanism of M.tb. resistance to the TB drug isoniazid (INH) conferred by loss of a sigma factor, SigI. We demonstrate that the gain of INH resistance in the M.tb. ΔsigI mutant might not diminish the organism's fitness for causing disease. These findings have significant implications when considering the ability of drug-resistant M.tb. strains to initiate untreatable TB epidemics, as it is possible that loss or alteration of SigI function could have a role in the generation of MDR and XDR M.tb. strains of suitable fitness to spread in a community setting.


Asunto(s)
Antituberculosos/farmacología , Isoniazida/farmacología , Mycobacterium tuberculosis/efectos de los fármacos , Mycobacterium tuberculosis/genética , Factor sigma/genética , Tuberculosis Resistente a Múltiples Medicamentos/microbiología , Animales , Proteínas Bacterianas/biosíntesis , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Catalasa/biosíntesis , Catalasa/genética , Farmacorresistencia Bacteriana Múltiple , Genes Bacterianos , Genes Reguladores , Macrófagos/inmunología , Macrófagos/microbiología , Ratones , Ratones Endogámicos BALB C , Mycobacterium tuberculosis/metabolismo , Mycobacterium tuberculosis/patogenicidad , Regulón , Transcripción Genética , Tuberculosis/tratamiento farmacológico , Tuberculosis/microbiología
6.
PLoS One ; 7(8): e43429, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22952680

RESUMEN

Mycobacterium tuberculosis, the etiologic agent of tuberculosis (TB) possesses at least five genes predicted to encode proteins with NlpC/P60 hydrolase domains, including the relatively uncharacterized Rv2190c. As NlpC/P60 domain-containing proteins are associated with diverse roles in bacterial physiology, our objective was to characterize Rv2190c in M. tuberculosis growth and virulence. Our data indicate that lack of Rv2190c is associated with impaired growth, both in vitro and during an in vivo mouse model of TB. These growth defects are associated with altered colony morphology and phthiocerol dimycocerosate levels, indicating that Rv2190c is involved in cell wall maintenance and composition. In addition, we have demonstrated that Rv2190c is expressed during active growth phase and that its protein product is immunogenic during infection. Our findings have significant implications, both for better understanding the role of Rv2190c in M. tuberculosis biology and also for translational developments.


Asunto(s)
Proteínas Bacterianas/genética , Regulación Bacteriana de la Expresión Génica , Mycobacterium tuberculosis/metabolismo , Tuberculosis/parasitología , Factores de Virulencia/genética , Animales , Proteínas Bacterianas/metabolismo , Femenino , Prueba de Complementación Genética , Lípidos/química , Ratones , Ratones Endogámicos BALB C , Microscopía Electrónica de Transmisión/métodos , Muramidasa/química , Mutación , Mycobacterium tuberculosis/genética , Fenotipo , Biosíntesis de Proteínas , Tuberculosis/metabolismo , Virulencia , Factores de Virulencia/metabolismo
7.
PLoS One ; 5(4): e10289, 2010 Apr 21.
Artículo en Inglés | MEDLINE | ID: mdl-20422019

RESUMEN

BACKGROUND: It has been hypothesized that the virulence of lab-passaged Mycobacterium tuberculosis and recombinant M. tuberculosis mutants might be reduced due to multiple in vitro passages, and that virulence might be augmented by passage of these strains through mice before quantitative virulence testing in the mouse or guinea pig aerosol models. METHODOLOGY/PRINCIPAL FINDINGS: By testing three M. tuberculosis H37Rv samples, one deletion mutant, and one recent clinical isolate for survival by the quantitative organ CFU counting method in mouse or guinea pig aerosol or intravenous infection models, we could discern no increase in bacterial fitness as a result of passaging of M. tuberculosis strains in mice prior to quantitative virulence testing in two animal models. Surface lipid expression as assessed by neutral red staining and thin-layer chromatography for PDIM analysis also failed to identify virulence correlates. CONCLUSIONS/SIGNIFICANCE: These results indicate that animal passaging of M. tuberculosis strains prior to quantitative virulence testing in mouse or guinea pig models does not enhance or restore potency to strains that may have lost virulence due to in vitro passaging. It is critical to verify virulence of parental strains before genetic manipulations are undertaken and comparisons are made.


Asunto(s)
Técnicas Bacteriológicas/normas , Mycobacterium tuberculosis/patogenicidad , Aerosoles , Animales , Aptitud Genética , Cobayas , Lípidos/análisis , Ratones , Modelos Animales , Mycobacterium tuberculosis/citología , Mycobacterium tuberculosis/genética , Proyectos de Investigación/normas , Eliminación de Secuencia , Pase Seriado , Tuberculosis/microbiología , Virulencia
8.
Antimicrob Agents Chemother ; 50(8): 2836-41, 2006 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16870781

RESUMEN

The seven Mycobacterium tuberculosis whiB-like genes encode small proteins postulated to be transcriptional regulators. A systematic real-time reverse transcription-PCR analysis following exposure to antibiotics and a variety of growth and in vitro stress conditions indicates differential, and in some cases dramatic, transcription modulations for the different M. tuberculosis whiB family members. This information together with biochemical analyses of the whiB1 to whiB7 gene products will be important for understanding the biology of this novel family of proteins in mycobacteria and related actinomycetes.


Asunto(s)
Antibacterianos/farmacología , Regulación Bacteriana de la Expresión Génica/efectos de los fármacos , Genes Bacterianos , Mycobacterium tuberculosis/efectos de los fármacos , Mycobacterium tuberculosis/genética , Estrés Oxidativo , Mycobacterium tuberculosis/crecimiento & desarrollo , Mycobacterium tuberculosis/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
9.
Proc Natl Acad Sci U S A ; 100(12): 7213-8, 2003 Jun 10.
Artículo en Inglés | MEDLINE | ID: mdl-12775759

RESUMEN

We describe a postgenomic in silico approach for identifying genes that are likely to be essential and estimate their proportion in haploid genomes. With the knowledge of all sites eligible for mutagenesis and an experimentally determined partial list of nonessential genes from genome mutagenesis, a Bayesian statistical method provides reasonable predictions of essential genes with a subsaturation level of random mutagenesis. For mutagenesis, a transposon such as Himar1 is suitable as it inserts randomly into TA sites. All of the possible insertion sites may be determined a priori from the genome sequence and with this information, data on experimentally hit TA sites may be used to predict the proportion of genes that cannot be mutated. As a model, we used the Mycobacterium tuberculosis genome. Using the Himar1 transposon, we created a genetically defined collection of 1,425 insertion mutants. Based on our Bayesian statistical analysis using Markov chain Monte Carlo and the observed frequencies of transposon insertions in all of the genes, we estimated that the M. tuberculosis genome contains 35% (95% confidence interval, 28%-41%) essential genes. This analysis further revealed seven functional groups with high probabilities of being enriched in essential genes. The PE-PGRS (Pro-Glu polymorphic GC-rich repetitive sequence) family of genes, which are unique to mycobacteria, the polyketide/nonribosomal peptide synthase family, and mycolic and fatty acid biosynthesis gene families were disproportionately enriched in essential genes. At subsaturation levels of mutagenesis with a random transposon such as Himar1, this approach permits a statistical prediction of both the proportion and identities of essential genes of sequenced genomes.


Asunto(s)
Genes Bacterianos , Mutagénesis Insercional , Mycobacterium tuberculosis/genética , Antibacterianos/farmacología , Secuencia de Bases , ADN Bacteriano/genética , Genes Bacterianos/efectos de los fármacos , Técnicas Genéticas , Genoma Bacteriano , Genómica , Familia de Multigenes , Mycobacterium tuberculosis/efectos de los fármacos , Sistemas de Lectura Abierta
10.
Infect Immun ; 72(3): 1733-45, 2004 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-14977982

RESUMEN

The Mycobacterium tuberculosis alternate sigma factor, SigF, is expressed during stationary growth phase and under stress conditions in vitro. To better understand the function of SigF we studied the phenotype of the M. tuberculosis DeltasigF mutant in vivo during mouse infection, tested the mutant as a vaccine in rabbits, and evaluated the mutant's microarray expression profile in comparison with the wild type. In mice the growth rates of the DeltasigF mutant and wild-type strains were nearly identical during the first 8 weeks after infection. At 8 weeks, the DeltasigF mutant persisted in the lung, while the wild type continued growing through 20 weeks. Histopathological analysis showed that both wild-type and mutant strains had similar degrees of interstitial and granulomatous inflammation during the first 12 weeks of infection. However, from 12 to 20 weeks the mutant strain showed smaller and fewer lesions and less inflammation in the lungs and spleen. Intradermal vaccination of rabbits with the M. tuberculosis DeltasigF strain, followed by aerosol challenge, resulted in fewer tubercles than did intradermal M. bovis BCG vaccination. Complete genomic microarray analysis revealed that 187 genes were relatively underexpressed in the absence of SigF in early stationary phase, 277 in late stationary phase, and only 38 genes in exponential growth phase. Numerous regulatory genes and those involved in cell envelope synthesis were down-regulated in the absence of SigF; moreover, the DeltasigF mutant strain lacked neutral red staining, suggesting a reduction in the expression of envelope-associated sulfolipids. Examination of 5'-untranslated sequences among the downregulated genes revealed multiple instances of a putative SigF consensus recognition sequence: GGTTTCX(18)GGGTAT. These results indicate that in the mouse the M. tuberculosis DeltasigF mutant strain persists in the lung but at lower bacterial burdens than wild type and is attenuated by histopathologic assessment. Microarray analysis has identified SigF-dependent genes and a putative SigF consensus recognition site.


Asunto(s)
Proteínas Bacterianas/genética , Genes Bacterianos , Mutación , Mycobacterium tuberculosis/genética , Mycobacterium tuberculosis/patogenicidad , Factor sigma/genética , Animales , Secuencia de Bases , Secuencia de Consenso , ADN Bacteriano/genética , Femenino , Perfilación de la Expresión Génica , Ratones , Ratones Endogámicos BALB C , Análisis de Secuencia por Matrices de Oligonucleótidos , Fenotipo , Regiones Promotoras Genéticas , Conejos , Tuberculosis Pulmonar/microbiología , Tuberculosis Pulmonar/patología
11.
Gastroenterology ; 126(2): 425-31, 2004 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-14762779

RESUMEN

BACKGROUND & AIMS: Familial adenomatous polyposis because of germline mutation of the adenomatous polyposis coli gene is characterized by development of colorectal adenomas and, ultimately, colorectal cancer. The usefulness of colorectal mucosal compounds to predict the effect on adenoma development of primary chemoprevention with the nonsteroidal anti-inflammatory drug sulindac was evaluated. METHODS: A randomized, double-blind, placebo-controlled study of 41 subjects genotypically affected with familial adenomatous polyposis but phenotypically unaffected was conducted. Patients received either sulindac or placebo for 48 months, and development of new adenomas was evaluated. The levels of 5 prostanoids, ornithine decarboxylase, and polyamines were measured serially in normal-appearing rectal mucosa. RESULTS: There were no statistically significant differences between treatment groups in baseline levels of prostanoids, ornithine decarboxylase, or polyamines. At conclusion of the study, 4 of 5 prostaglandin levels were statistically significantly lower in the sulindac group than in the placebo group. Among the subset of patients taking sulindac, 3 of 5 prostaglandin levels were statistically significantly lower in patients who were polyp free than in those who developed polyps. By contrast, there were no statistically significant differences in ornithine decarboxylase or polyamines between treatment groups or in those on sulindac who were polyp free compared with those who developed polyps. CONCLUSIONS: Colorectal mucosal prostaglandin levels, but not ornithine decarboxylase or polyamines, may be valuable biomarkers to assess appropriate drug dosage and medication compliance in patients undergoing primary chemoprevention therapy with sulindac. Reduction of mucosal prostaglandin levels may be necessary to achieve chemopreventive benefit from this agent.


Asunto(s)
Poliposis Adenomatosa del Colon/diagnóstico , Poliposis Adenomatosa del Colon/prevención & control , Colon/metabolismo , Inhibidores de la Ciclooxigenasa/uso terapéutico , Ornitina Descarboxilasa/metabolismo , Poliaminas/metabolismo , Prostaglandinas/metabolismo , Sulindac/uso terapéutico , Poliposis Adenomatosa del Colon/genética , Poliposis Adenomatosa del Colon/metabolismo , Método Doble Ciego , Genotipo , Humanos , Mucosa Intestinal/metabolismo , Fenotipo , Insuficiencia del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA